Cite
HARVARD Citation
Crabtree, T. et al. (2022). Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon‐like peptide‐1 receptor agonists. Diabetes, obesity & metabolism. 24 (7), pp. 1398-1401. [Online].